Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL95351 | 0.75 | CLTC (0.44) | CA1CA2CA7CA12CA9 | |
| Lithium Ion SCHEMBL29875131 | 0.75 | CLTC (0.44) | CA1CA2CA7CA12CA9 | |
| SCHEMBL1443489 | 0.73 | CA1 (0.40) | CA1CA2CA7CA12CA9 | |
| SCHEMBL31305335 | 0.67 | CA1 (0.50) | CA1CA2CA7CA12CA9 | |
| Lithium Ion SCHEMBL16937435 | 0.67 | STK10 (0.33) | — | |
| SCHEMBL28451650 | 0.66 | KMT2A (0.37) | CA1CA2CA7CA12CA9 | |
| SCHEMBL28898006 | 0.65 | KMT2A (0.36) | CA1CA2CA7CA12CA9 | |
| SCHEMBL13870630 | 0.65 | KMT2A (0.39) | CA1CA2CA7CA12CA9 | |
| SCHEMBL54845 | 0.61 | TSHR (0.50) | CA1CA2CA12CA9 | |
| SCHEMBL1376919 | 0.60 | ALDH1A1 (0.62) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189503-A1 | NOVEL NUCLEIC ACID DERIVATIVE INTO WHICH GIVEN COMPOUND HAS BEEN INTRODUCED AND METHOD FOR PRODUCING THE SAME | Biodynamics Laboratory, INC. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090090628-A1 | NUCLEIC ACID DERIVATIVES AND METHODS OF USE | BIODYNAMICS LABORATORY, INC (JP) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090090628-A1 | NUCLEIC ACID DERIVATIVES AND METHODS OF USE | NSUN3, TRDMT1, NSUN2 | CA1 2759/4885CA2 3497/4885CA7 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.